CAS 1715025-32-3

Fórmula: C26H27BrF3N5O2

InChI: InChI=1S/C26H27BrF3N5O2/c1-32-11-21(15-6-16(27)10-17(28)7-15)35-26(37)18-4-2-14(9-19(18)29)24-25(31)33-12-22(34-24)13-3-5-23(36)20(30)8-13/h2,4,6-7,9-10,12-13,20-21,23,32,36H,3,5,8,11H2,1H3,(H2,31,33)(H,35,37)/t13-,20-,21+,23-/m0/s1

Clave InChI: YFCIFWOJYYFDQP-PTWZRHHISA-N

SMILES: CNC[C@H](C1=CC(=CC(=C1)Br)F)NC(=O)C2=C(C=C(C=C2)C3=NC(=CN=C3N)[C@H]4CC[C@@H]([C@H](C4)F)O)F

Rineterkib

CAS: 1715025-32-3

Rineterkib

Fórmula: C₂₆H₂₇BrF₃N₅O₂

Pureza: ≥98%

Peso molecular: 578.42

Ref: 54-BUP09164

ERK-IN-1

CAS: 1715025-32-3

ERK-IN-1 is a selective inhibitor of the mitogen-activated protein kinase. It has been shown to inhibit proliferation of cells in culture and may be useful for treating metastatic melanoma and other cancers. ERK-IN-1 inhibits the activity of CDK4/6, which are enzymes that regulate cell division. This inhibition leads to decreased cell proliferation and tumor growth, which is responsible for its antineoplastic activity. ERK-IN-1 also inhibits signal transduction pathways in cells, which may lead to cancer prevention.

Fórmula: C₂₆H₂₇BrF₃N₅O₂

Pureza: Min. 95%

Peso molecular: 578.4 g/mol

Ref: 3D-QTC02532

Rineterkib

CAS: 1715025-32-3

Rineterkib (ERK-IN-1) is an inhibitor of RAF and ERK1/2 activating mutations in the MAPK pathway.

Fórmula: C₂₆H₂₇BrF₃N₅O₂

Pureza: 99.73%

Forma y color: Solid

Peso molecular: 578.424

Ref: TM-T11224